Oral Anti Diabetic Agents in the Hospital

Launched by EMORY UNIVERSITY · Jun 2, 2020

Keywords

ClinConnect Summary

In this clinical trial, researchers are studying whether continuing the use of patients' home oral diabetes medications during their hospital stay is a safe and effective alternative to using insulin for managing diabetes. The main goal is to see how well these oral medications control blood sugar levels compared to a standard insulin treatment method in patients with type 2 diabetes.

Eligible participants are adults between 18 and 80 years old who have been diagnosed with type 2 diabetes and are currently taking oral medications for their condition. To participate, their blood sugar levels upon admission should be below 250 mg/dl, and they should not be receiving insulin at that time. If you choose to take part in the trial, you will be closely monitored for your blood sugar levels while being treated in the hospital. This study is currently recruiting participants, and it aims to find better ways to manage diabetes for patients during their hospital stays.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males or females, age 18-80 years admitted to a general medicine and surgery services
• • Known history of T2D receiving OADs either as monotherapy or in combination therapy
• • Admission BG \< 250 mg/dl or randomization BG \<250 mg/dl and not receiving basal insulin
• • Patients receiving OADs in combination with GLP-1 receptor agonists (GLP-1RA) who have HbA1c \<7.5% within the past three months
• • HbA1c \<10%
• Exclusion Criteria:
• • No known history of diabetes
• • Laboratory evidence of diabetic ketoacidosis
• • Subjects with a history of type 1 diabetes (suggested by BMI \< 25 requiring insulin therapy or with a history of diabetic ketoacidosis, or ketonuria)
• • Meeting any exclusion criteria based on specific contraindications to their home oral therapy
• • Acute critical illness or cardiac surgery expected to require admission to a critical care unit
• • Gastrointestinal obstruction, adynamic ileus, or expected to require gastrointestinal suction
• • Medical or surgical patients expected to be kept NPO for \>24-48 hours after admission or after completion of surgical procedure
• • Impaired renal function (eGFR \<30 ml/min)
• • Current treatment with oral or injectable corticosteroid
• • Mental condition rendering the subject unable to understand the nature and scope of the study
• • Female subjects who are pregnant or breastfeeding at time of enrollment in the study
• • New or recent onset (within two weeks) of coronavirus disease 2019 (COVID-19) infection at the time of admission